Work

Raltegravir Demonstrates Durable Efficacy Through 96 Weeks: Results from STARTMRK, A Phase III Study of Raltegravir-b ased vs. Efavirenz-based Therapy in Treatment-Naï

Year: 2009

Type: article

Study design: Clinical Trial

Authors: JL Lennox, E DeJesus, Adriano Lazzarin, D. Berger, Richard B. Pollard, JV Madruga, Jiao Zhao, Christopher L. Gilbert, Angela Rodgers, Hedy Teppler, Randi Y. Leavitt, Jeffrey L. Lennox

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2187620446

FWCI:

Cites:

Cited by:

Related to: 10